Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: The prognosis of elderly patients with Hodgkin lymphoma (HL) unfit for conventional chemotherapy remains poor. We report the results of the LYSA phase II NIVINIHO trial in treatment-naive HL patients aged ≥ 61 years with comorbidities contraindicating standard chemotherapy. Treatment included an induction phase with nivolumab alone, followed by a consolidation phase: either nivolumab monotherapy for patients with early complete metabolic response or nivolumab plus vinblastine for patients with stable disease or partial response. The primary objective of the study was the complete metabolic response (CMR) rate at the end of treatment. From August 2018 to April 2020, 64 patients were enrolled. Median age was 75.0 (range, 62 to 91) years, Ann Arbor stage was advanced (stage III-IV) in 75.0% of patients. At end of nivolumab induction, 11 patients (17.2%) achieved CMR and were consolidated with nivolumab alone, 23 (35.9%) patients obtained PMR or SD and received vinblastine plus nivolumab. Among the 56 evaluable patients, 16 (28.6%) achieved CMR at the end of treatment. With a median follow-up of 24.4 months (range, 0.9 to 35.2), median progression-free survival (PFS) was 9.8 months (95% confidence interval [CI], 4.2 to 12) while the 2-year overall survival (OS) rate was 74.1% (95%CI, 58.9% to 84.4%). Thirtytwo patients (50%) experienced grade ≥ 3 adverse events (AEs). Nivolumab-related adverse events led to treatment discontinuation in 19 patients (29.7%). Our results show that nivolumab can be administrated to elderly, frail patients unfit for classical chemotherapy; however, the objective response rate with monotherapy remains low. Trial registration number: NCT03580408.
Source: Haematologica
Authors: Julien Lazarovici, Sandy Amorim, Krimo Bouabdallah, Marguerite Fournier, Stéphanie Guidez, Lysiane Molina, Franck Morschhauser, Baptiste Delapierre, Thomas Gastinne, Kamel Laribi, Vincent Launay, Bohrane Slama, Nawel Belmecheri, René-Olivier Casasnovas, Anne Corby, Eric Durot, Pierre Feugier, Emmanuelle Nicolas-Virelizie, David Sibon, Alina Berriolo-Riedinger, Véronique Edeline, Thierry Vander Borght, Diane Damotte, Alexandra Traverse-Glehen, Vincent Ribrag, Marc André
Institutions: Institut Gustave Roussy, Centre Hospitalier Universitaire de Bordeaux, The Lymphoma Academic Research Organisation, Hôpital Lyon Sud, Centre Hospitalier Universitaire de Poitiers, Centre Hospitalier Universitaire de Grenoble, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Nantes, Centre Hospitalier de Saint-Brieuc, Institut Paoli-Calmettes, CHU Dijon Bourgogne, Centre Hospitalier de La Rochelle, Centre Hospitalier Universitaire de Reims, Centre Hospitalier Régional et Universitaire de Nancy, Centre Léon Bérard, Hôpital Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, Centre Georges François Leclerc, UCLouvain, Université Paris Cité, Hôpitaux Universitaires Paris-Ouest, Hospices Civils de Lyon
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W7162683629
FWCI:
Cites:
Cited by:
Related to: